IC
PTGX icon

Innealta Capital’s Protagonist Therapeutics PTGX Stock Holding History

Innealta Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42
Closed -$1.46K – 1297
2024
Q2 		$1.46K Buy
+42
New +$1.23K ﹤0.01% 1201

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Innealta Capital's PTGX Position: Q3 2024 in Review

Innealta Capital sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 42 shares — an estimated $1.46K sold.

Innealta Capital first reported a position in PTGX in Q2 2024 and held it in 1 quarter. The position peaked at $1.46K in Q2 2024. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Innealta Capital reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 42 Protagonist Therapeutics shares in Q3 2024, an estimated $1.46K.
  • Innealta Capital first reported a position in Protagonist Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Protagonist Therapeutics position peaked at $1.46K in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.